PT2146714E - Utilização de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxidopiridin- 4-il)-5-(metoxi)piridina-2-carboxamida para o tratamento dos distúrbios motores relacionados com a doença de parkinson - Google Patents

Utilização de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxidopiridin- 4-il)-5-(metoxi)piridina-2-carboxamida para o tratamento dos distúrbios motores relacionados com a doença de parkinson Download PDF

Info

Publication number
PT2146714E
PT2146714E PT08787963T PT08787963T PT2146714E PT 2146714 E PT2146714 E PT 2146714E PT 08787963 T PT08787963 T PT 08787963T PT 08787963 T PT08787963 T PT 08787963T PT 2146714 E PT2146714 E PT 2146714E
Authority
PT
Portugal
Prior art keywords
oxidopyridin
cyclopropylmethoxy
carboxamide
parkinson
dichloro
Prior art date
Application number
PT08787963T
Other languages
English (en)
Portuguese (pt)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT2146714E publication Critical patent/PT2146714E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PT08787963T 2007-04-19 2008-04-16 Utilização de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxidopiridin- 4-il)-5-(metoxi)piridina-2-carboxamida para o tratamento dos distúrbios motores relacionados com a doença de parkinson PT2146714E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
PT2146714E true PT2146714E (pt) 2011-09-02

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
PT08787963T PT2146714E (pt) 2007-04-19 2008-04-16 Utilização de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxidopiridin- 4-il)-5-(metoxi)piridina-2-carboxamida para o tratamento dos distúrbios motores relacionados com a doença de parkinson

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015006807A (es) * 2012-11-28 2016-01-14 Sanofi Sa Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
CN122055155A (zh) * 2023-10-12 2026-05-15 美德阿利克斯株式会社 经皮吸收组合物
CN122421966A (zh) * 2023-10-12 2026-07-17 傲拓神经科学公司 用替伐普兰治疗神经精神病症

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ZA945609B (en) * 1993-07-28 1995-05-12 Rhone Poulenc Rorer Ltd [Di(ether or thioether)heteroaryl or fluoro substituted aryl] compounds
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
DE60018470T2 (de) * 1999-12-23 2006-02-16 Icos Corp., Bothell Cyclische amp spezifische phosphodiesterase inhibitoren
US20030069169A1 (en) * 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
US20060004056A1 (en) * 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
NZ542670A (en) * 2003-03-12 2008-11-28 Celgene Corp N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
US20070049611A1 (en) * 2005-06-10 2007-03-01 Talamas Francisco X Phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
US20100130554A1 (en) 2010-05-27
NZ580482A (en) 2011-10-28
AU2008257322A1 (en) 2008-12-04
MY148092A (en) 2013-02-28
ES2367408T3 (es) 2011-11-03
ATE513548T1 (de) 2011-07-15
ME00935B (me) 2012-06-20
SI2146714T1 (sl) 2011-10-28
TW200911247A (en) 2009-03-16
HRP20110666T1 (hr) 2011-10-31
PL2146714T3 (pl) 2011-10-31
EP2146714A1 (fr) 2010-01-27
MX2009011284A (es) 2009-11-02
CN101663035A (zh) 2010-03-03
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
IL201448A (en) 2014-08-31
CL2008001136A1 (es) 2009-01-16
EA200970970A1 (ru) 2010-02-26
PA8776801A1 (es) 2008-11-19
FR2915100A1 (fr) 2008-10-24
MA31367B1 (fr) 2010-05-03
IL201448A0 (en) 2010-05-31
KR20150004885A (ko) 2015-01-13
KR20090130059A (ko) 2009-12-17
CN101663035B (zh) 2012-06-20
TWI439269B (zh) 2014-06-01
ZA200907251B (en) 2011-04-28
KR101503942B1 (ko) 2015-03-18
JO2678B1 (en) 2013-03-03
UY31035A1 (es) 2008-11-28
WO2008145841A1 (fr) 2008-12-04
CA2684174C (fr) 2014-02-25
RS51869B (sr) 2012-02-29
FR2915100B1 (fr) 2009-06-05
JP5386478B2 (ja) 2014-01-15
EA019194B1 (ru) 2014-01-30
CA2684174A1 (fr) 2008-12-04
HK1141725A1 (en) 2010-11-19
CY1111840T1 (el) 2015-10-07
AU2008257322B2 (en) 2013-06-13
AR066108A1 (es) 2009-07-22
EP2146714B1 (fr) 2011-06-22
JP2010524906A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
ZA200909191B (en) Catecholamine derivatives useful for the treatment of parkinson's disease
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
PL2229369T3 (pl) Pochodne 6,7-dialkoksychinazoliny użyteczne do leczenia zaburzeń związanych z rakiem
AU2008233088A8 (en) Calcimimetic compounds for use in the treatment of bowel disorders
IL206107A0 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
IL199214A0 (en) New combination for use in the treatment of inflammatory disorders
SI2146714T1 (sl) Uporaba 4-ciklopropilmetoksi-N-(3,5-dikloro-1-oksido-piridin-4-il)-5-(metoksi) priridin-2-karboksamida za zdravljenje motoričnih motenj, povezanih s Parkinsonovo boleznijo
IL201451A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of spinal cord traumas
PL1907374T3 (pl) Pochodne benzylopiperazyny użyteczne do leczenia zaburzeń układu pokarmowego
EP2099444A4 (en) USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
PL2146713T3 (pl) Zastosowanie 4-cyklopropylometoksy-N-(3,5-dichloro-1-oksydo-pirydyn-4-ylo)-5-(metoksy)pirydyno-2-karboksyamidu do leczenia urazów mózgowych
HK1134650A (en) New combination for use in the treatment of inflammatory disorders
IL194275A0 (en) Use of digitalis-like compounds in the treatment of affective disorders
ZA200904249B (en) New combination for use in the treatment of inflammatory disorders